Idaho is currently home to 368 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boise, Meridian, Idaho Falls and Nampa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
NCT02339571
Recruiting
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Register for Updates
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136
Recruiting
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD. Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This stud... Read More
Gender:
All
Ages:
Between 18 years and 63 years
Trial Updated:
06/19/2024
Locations: Treasure Valley Medical Research /ID# 263738, Boise, Idaho
Conditions: Atopic Dermatitis
Register for Updates
A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout
NCT06229145
Recruiting
The study consists of 24-week double-blind trial to evaluate the non-inferiority of the efficacy and safety of pegloticase Q4W with MTX versus pegloticase Q2W with MTX, followed by a 24-week open-label extension of pegloticase Q4W with MTX, in participants with uncontrolled refractory gout. The main objective of the study is to evaluate the effect of pegloticase 16 mg administered Q4W with MTX versus pegloticase 8 mg administered Q2W with MTX, on the response rate during Month 6, as measured by... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Velocity Clinical Research - Boise, Meridian, Idaho
Conditions: Gout
Register for Updates
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
NCT06177912
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V116 compared to PPSV23 in children 2 through 17 years of age. Researchers want to learn if V116 is as good as, or is better than the PPSV23 vaccine in terms of the antibody immune response. V116 and PPSV23 will be studied in children and teenagers who have a higher risk of getting invasive pneumococcal disease (IPD).
Gender:
All
Ages:
Between 2 years and 17 years
Trial Updated:
06/19/2024
Locations: Bingham Memorial Hospital ( Site 0149), Blackfoot, Idaho
Conditions: Pneumococcal Infection
Register for Updates
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760
Recruiting
The goal of this study is to evaluate V940 plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of completely resected (R0) Stage II, IIIA, IIIB (with nodal involvement [N2]) non-small cell lung cancer (NSCLC). The primary hypothesis is that V940 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS) as assessed by the investigator.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Beacon Cancer Care ( Site 0044), Post Falls, Idaho
Conditions: Non-small Cell Lung Cancer
Register for Updates
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
NCT06029270
Recruiting
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the co... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
Register for Updates
Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer
NCT05904080
Recruiting
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho
Conditions: Stage IV Nasopharyngeal Carcinoma AJCC v8, Nasopharyngeal Carcinoma
Register for Updates
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
NCT05882877
Recruiting
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
06/19/2024
Locations: Treasure Valley Medical Research, Boise, Idaho
Conditions: Atopic Dermatitis
Register for Updates
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
NCT05882045
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Elite Clinical Trials, Blackfoot, Idaho
Conditions: Obesity, Cardiovascular Diseases
Register for Updates
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05735483
Recruiting
The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to <18 years of age with moderate-to-severe atopic dermatitis
Gender:
All
Ages:
Between 6 months and 18 years
Trial Updated:
06/19/2024
Locations: Treasure Valley Medical Research, Boise, Idaho
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
NCT05726227
Recruiting
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dumm... Read More
Gender:
All
Ages:
Between 6 years and 18 years
Trial Updated:
06/19/2024
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity
Register for Updates
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)
NCT05704738
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subjects.
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
06/19/2024
Locations: Treasure Valley Medical Research, Boise, Idaho
Conditions: Atopic Dermatitis
Register for Updates